Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL109668 | 0.89 | CYP2D6 (0.34) | ALDH1A1CYP1A2USP2LMNA | |
| Pyrimidine SCHEMBL6585223 | 0.80 | TDP1 (0.33) | CYP1A2 | |
| SCHEMBL12615558 | 0.74 | MEN1 (0.43) | ALDH1A1CYP1A2USP2 | |
| SCHEMBL3689268 | 0.70 | SMN1; SMN2 (0.42) | MAPK1ALDH1A1CYP1A2CHRM2CHRM1 | |
| SCHEMBL29893529 | 0.69 | KDM4E (0.33) | ALDH1A1 | |
| SCHEMBL11064389 | 0.69 | TLR8 (0.37) | — | |
| SCHEMBL28893694 | 0.68 | CYP1A2 (0.32) | CYP1A2 | |
| SCHEMBL5719734 | 0.68 | L3MBTL1 (0.32) | MAPK1ALDH1A1CYP1A2LMNA | |
| SCHEMBL17584302 | 0.68 | — | — | |
| Oxirane SCHEMBL1798956 | 0.68 | ALDH1A1 (0.31) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575152-B2 | Non-steroidal compounds useful as glucocorticoid receptor modulators | MERCK SHARP & DOHME B.V. (NL) | 2013-11-05 | — | — | US | disclosed |
| EP-1924580-B1 | NON-STEROIDAL COMPOUNDS USEFUL AS GLUCOCORTICOID RECEPTOR MODULATORS | ORGANON NV (NL) | 2009-01-21 | — | — | EP | disclosed |
| US-20080188459-A1 | Non-Steroidal Compounds Useful as Glucocorticoid Receptor Modulators | N.V. ORGANON (NL) | 2008-08-07 | — | — | US | disclosed |
| EP-1924580-A1 | NON-STEROIDAL COMPOUNDS USEFUL AS GLUCOCORTICOID RECEPTOR MODULATORS | N.V. Organon (NL) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025938-A1 | NON-STEROIDAL COMPOUNDS USEFUL AS GLUCOCORTICOID RECEPTOR MODULATORS | N.V. ORGANON (NL) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188459-A1 | Non-Steroidal Compounds Useful as Glucocorticoid Receptor Modulators | NR3C1, NR3C2, MC2R | MAPK1 815/4885ALDH1A1 2468/4885CYP1A2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.